Baird analyst Joel Beatty lowered the firm’s price target on PTC Therapeutics (PTCT) to $66 from $70 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results and where PKU PDUFA date is in July.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics: Strong Revenue Performance and Promising Pipeline Present Compelling Buy Opportunity
- PTC Therapeutics price target lowered to $67 from $75 at JPMorgan
- PTC Therapeutics: Strong Financial Performance and Promising Product Launches Justify Buy Rating
- PTC Therapeutics upgraded to Neutral from Sell at Citi
- PTC Therapeutics Reports Strong Q1 2025 Results